Bisphenol A and Muscle Insulin Sensitivity

California Polytechnic State University (Cal Poly)

Status: Completed

Conditions: Glucose Metabolism Disorders; Microtia; Insulin Sensitivity

Treatments: Behavioral: bisphenol A; Behavioral: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03771066

2018-149-CP

Details and patient eligibility

About

This study examine oral bisphenol A consumption on muscle insulin sensitivity and hepatic glucose suppression. Half of the participants will receive a diet plus BPA and the other half will receive a diet plus no bisphenol A.

Full description

Evidence linking bisphenol A exposure with diabetes risk remains mainly associative in nature, and mechanism linking bisphenol A to type 2 diabetes remains unclear. The investigator's preliminary data suggests that in young adults, single oral BPA consumption significantly decreased glucose, insulin, and C-Peptide responses to an oral glucose tolerance test, suggesting that immediate consumption of bisphenol A has an effect on muscle insulin sensitivity, hepatic glucose suppression and/or digestion and absorption to lower blood glucose, insulin, and C-Peptide concentrations. The present experimental study evaluating the effects of bisphenol A over several days on the pathogenesis of type 2 diabetes will directly assess each of these potential mechanisms using gold standard measures (euglycemic hyperinsulinemic clamp technique and hepatic glucose suppression with glucose stable isotope infusion, and fecal microbiota).

Enrollment: 40 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• non-dieting
• sedentary (≤3 hour/week of aerobic exercise)
• normal-weight (BMI = 18.5 to 24.9 kg/m2)
• weight-stable for the previous 6 months
• free of any metabolic or chronic disease
• non-smoking, and sedentary

Exclusion criteria

• Hemoglobin A1C based on the American Diabetes Association guidelines of 5.7 to 6.4% (Prediabetes) or >6.4% (Diabetes)
• impaired glucose tolerance
• type 1 diabetes
• type 2 diabetes
• colitis or any inflammatory bowel condition
• neurologic or psychiatric conditions
• smoking
• special diets (e.g. vegetarian, low-carbohydrate, Paleolithic, etc.)
• pregnant women or women trying to become pregnant

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 2 patient groups, including a placebo group

Diet plus bisphenol A

Experimental group

Description:

Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.

Treatment:

Behavioral: bisphenol A

Placebo

Placebo Comparator group

Description:

Participants will receive a 4-day diet plus no bisphenol A.

Treatment:

Behavioral: Placebo